↓ Skip to main content

EUREKA study – the evaluation of real-life use of a biophotonic system in chronic wound management: an interim analysis

Overview of attention for article published in Drug Design, Development and Therapy, December 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
1 news outlet
facebook
1 Facebook page

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
179 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
EUREKA study – the evaluation of real-life use of a biophotonic system in chronic wound management: an interim analysis
Published in
Drug Design, Development and Therapy, December 2017
DOI 10.2147/dddt.s142580
Pubmed ID
Authors

Marco Romanelli, Alberto Piaggesi, Giovanni Scapagnini, Valentina Dini, Agata Janowska, Elisabetta Iacopi, Carlotta Scarpa, Stéphane Fauverghe, Franco Bassetto

Abstract

Interest has grown regarding photobiomodulation (PBM) with low-level light therapy, which has been shown to positively affect the stages of the wound healing process. In a real-life context clinical setting, the objective of the EUREKA study was to investigate efficacy, safety, and quality of life associated with the use of a BioPhotonic gel (LumiHeal™) in the treatment of chronic wounds such as venous leg ulcers (VLUs), diabetic foot ulcers (DFUs), and pressure ulcers (PUs). This BioPhotonic gel represents a new, first-in-class emission spectrum of light, including fluorescence, to induce PBM and modulate healing. The multicenter, prospective, interventional, uncontrolled, open-label study enrolled 100 patients in 12 wound centers in Italy. We performed an early interim analysis based on the first 33 subjects (13 VLU, 17 DFU, 3 PU) in seven centers who completed the study. Seventeen patients (52%) achieved total wound closure (full re-epithelialization for 2 weeks) during the study period. Two patients (6%) were considered "almost closed" (decrease of the wound area of more than 90% at study end) and three others (9%) were considered "ready for skin grafting". No related serious adverse events were observed, and the compliance was excellent. After the treatment, the average time to "pain-free" was 11.9 days in the VLU group. Quality of life was improved with overall increase of 26.4% of the total score (Cardiff Wound Impact Schedule, p=0.001). The study revealed a positive efficacy profile of the BioPhotonic gel in promoting wound healing and reactivating the healing process in different types of chronic, hard-to-heal wounds. The treatment was shown to be safe and well tolerated by the patients, and a reduction of pain perception was also detected during the treatment period. The improvement of the quality of life was accompanied by a high level of clinician satisfaction.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 179 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 179 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 34 19%
Student > Master 17 9%
Other 13 7%
Researcher 11 6%
Professor 9 5%
Other 26 15%
Unknown 69 39%
Readers by discipline Count As %
Nursing and Health Professions 51 28%
Medicine and Dentistry 24 13%
Agricultural and Biological Sciences 8 4%
Biochemistry, Genetics and Molecular Biology 5 3%
Psychology 3 2%
Other 13 7%
Unknown 75 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2021.
All research outputs
#4,762,265
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#291
of 2,268 outputs
Outputs of similar age
#93,324
of 444,941 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 45 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 444,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.